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cu.2012.Abstract Increased fructose consumption is strongly associated with metabolic syndrome (MS).
This study was performed to elucidate the role of co-enzyme Q10 (CoQ) and/or rosiglitazone (Rosi)
in fructose induced MS. Four groups of rats (n= 8–10) were fed on fructose-enriched diet (FED)
for 16 weeks. One served as FED-control while the remaining groups were treated with CoQ
(10 mg/kg/day), Rosi (4 mg/kg/day) or their combination during the last 6 weeks. Another group
was fed on normal laboratory chow (normal control). At the end of the experiment, blood samples
were collected for estimation of markers related to MS. In addition, histological examination of
liver, kidney and pancreas samples was done. Induction of the MS was associated with increased
body weight gain (34%) coupled with elevated levels of blood glucose (48%), insulin (86%), insulin
resistance (270%), uric acid (69%), urea (155%), creatinine (129%) and blood lipids with different
degrees. Fructose-induced MS also reduced plasma catalase (62%) and glutathione peroxidase
(89%) activities parallel to increased serum leptin and tumor necrosis factor-alpha (TNF-a) levels.
These changes were coupled by marked histological changes in the examined tissues. Treatment
with CoQ or Rosi attenuated most of MS-induced changes. Besides, the combination of both agents
further reduced blood glucose, total cholesterol, triglycerides and urea levels, as well as, normalized
serum levels of leptin and TNF-a. In addition, combined therapy of both agents elevated HDL-
cholesterol level and glutathione peroxidase activity. In conclusion, the present study proves the
beneﬁts of co-supplementation of CoQ and Rosi in a fructose-induced model of insulin resistance.
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10.0011. Introduction
The metabolic syndrome (MS) is a constellation of risk factors
for cardiovascular disease and type-2 diabetes that consist of
abdominal obesity, dyslipidemia, hyperuricemia, b-cell dys-
function, insulin resistance, and hyperglycemia.1 One of the
most important causes that contributes to the growing world-
wide prevalence of MS, obesity and type-2 diabetes is the
change of dietary habits principally due to the increased intakehosting by Elsevier B.V. Open access under CC BY-NC-ND license.
14 S.M. Mansour et al.of simple sugars, mainly fructose, commonly used in food
industry and sugar-sweetened drink.2
Co-enzyme Q10 (CoQ) is an oil-soluble, vitamin-like sub-
stance present in most eukaryotic cells, primarily in the mito-
chondria. It is a component of the electron transport chain
(ETC) and participates in aerobic cellular respiration, generat-
ing 95% of human body energy in the form of ATP.3 CoQ has
been reported to lower glycated hemoglobin levels and lipid
peroxidation parallel to increasing the level of some antioxi-
dant enzymes in the pancreas of diabetic rats.4 Furthermore,
it has been found that supplementation of CoQ to streptozoto-
cin (STZ)-diabetic rats attenuated most of diabetic-induced
changes in oxidative stress.5
Rosiglitazone (Rosi) is a highly potent and selective agonist
for peroxisome proliferator activated receptor-c (PPAR-c).6
Its primary action is the improvement of insulin sensitivity in
the muscles and adipose tissue, as well as, inhibition of hepatic
gluconeogenesis.
The present work was therefore carried out to further
investigate the possible beneﬁcial role of CoQ in fructose-
induced insulin resistance syndrome alone or in combination
with Rosi.
2. Materials and Methods
2.1. Drugs and chemicals
CoQ and Rosi were kindly provided as ﬁnely dispersible pow-
ders by MEPACO Pharmaceutical Company (Egypt) and
Memphis Pharmaceutical Company (Egypt), respectively.
They were suspended in 1% tween 80 shortly before adminis-
tration to animals. The concentrations of the drugs were ad-
justed so that each 100 g of animal’s body received orally
1 ml of either suspension containing the required dose. Fruc-
tose was purchased from Elnasr-Pharma, Egypt. Mineral and
vitamin mixtures were obtained from Sigma–Aldrich, USA.
All other chemicals were of the highest grade commercially
available.
2.2. Animals
Male Wistar albino rats, 120–140 g body weight, were pur-
chased from the National Cancer Institute, Cairo, Egypt and
left to accommodate in the animal facility of the Faculty of
Pharmacy, Cairo University, for 1 week before being subjected
to experimentation. All animals were allowed free access to
diet and tap water. The study was conducted in accordance
with ethical procedures and policies approved by the Ethics
Committee of Faculty of Pharmacy, Cairo University.
2.3. Induction of insulin-resistance syndrome
Insulin-resistance was induced by feeding rats a fructose-en-
riched diet (FED) for 10 weeks according to the method
described by Bezerra and coworkers.7 FED was composed
of fructose (660 g/kg), soya protein (200 g/kg), sheep fat
(60 g/kg), cellulose (30 g/kg), L-lysine (10 g/kg), choline chlo-
ride (10 g/kg), DL-methionine (10 g/kg), mineral mixture
(10 g/kg) and vitamin mixture (10 g/kg). Diet was freshly pre-
pared every 3–4 days and stored at 2–8 C till used.2.4. Experimental design
Rats were provided with a FED for 10 weeks. Blood samples
were collected randomly after 4, 6, 8 and 10 weeks from the
initiation of the FED. Serum levels of fasting blood glucose
(FBG), triglycerides (TGs) and total cholesterol were esti-
mated to ensure the induction of insulin-resistance syndrome.
FED-fed rats were randomly allocated into 4 groups (8–10 rats
each). One group served as FED-fed control group, while the
other 3 groups were treated orally with CoQ (10 mg/kg/day),8
Rosi (4 mg/kg/day)9 or their combination, respectively for
6 weeks. Animals were maintained on the FED during the
treatment period. A group of animals consisting of 10 rats
was run concurrently and maintained on standard rat chow
diet and assigned as the normal-control group. Body weight
was recorded once weekly.
By the end of the treatment period, animals were fasted for
12 h and blood samples were withdrawn from the retro-orbital
plexus for the estimation of the levels of FBG, insulin, lipids,
leptin, tumor necrosis factor-alpha (TNF-a), creatinine, uric
acid and urea. In addition, homeostasis model assessment of
insulin resistance (HOMA-IR score) as an indicator of insulin
resistance and LDL-cholesterol (LDL-C) level were calculated.
Plasma activities of catalase and glutathione peroxidase (GSH-
Px) enzymes were also estimated as oxidative stress biomark-
ers. Samples of liver, kidney and pancreas from each group
were preserved in 10% formalin prepared in saline and kept
for histological examination.2.5. Determination of biochemical parameters
FBG level (mg/dl) is oxidized enzymatically to yield a red vio-
let quinoneimine that can be determined colorimetrically using
a test reagent kit (EMAPOL, Poland); whereas serum insulin
level (lIU/ml) was predicted following a solid phase two-site
enzyme immunoassay (DRG Instruments GmbH, Germany).
The obtained values of both FBG and insulin levels were then
used to calculate insulin resistance as described by Matthews
et al.10
Insulin resistanceðHOMA-IRÞscore
¼ serum glucoseðmmol=lÞ  serum insulinðlIU=mlÞ=22:5
ð1Þ
The serum levels of leptin (ng/ml) and TNF-a (pg/ml) were
also estimated by solid-phase enzyme-linked immunosorbent
assay (ELISA) based on the sandwich principle using test re-
agent kits (DRG Instruments, GmbH, Germany) and (ID labs,
Canada), respectively.
Total cholesterol (mg/dl) and HDL-C (mg/dl) levels were
determined following their hydrolysis and oxidation to yield
colored quinoneimine derivatives using test reagent kits (Biodi-
agnostics, Egypt). TGs level (mg/dl) was estimated by a re-
agent kit (EMAPOL, Poland), in which TGs were
hydrolyzed with lipoprotein lipase to form glycerol, which
forms a complex with H2O2 giving a colored derivative. The
obtained levels of total cholesterol, HDL-C and TGs were then
used to calculate the serum level of LDL-C as that described
by Friedewald et al.11
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Kidney function tests including the levels (mg/dl) of uric
acid, urea and creatinine were performed using test reagent kits
(Biodiagnostics, Egypt). In addition, the activities of some
antioxidant enzymes including catalase (IU/l) and GSH-Px
(U/ml) were estimated using test reagent kits (Biodiagnostics,
Egypt) and (Cayman, USA), respectively.
2.6. Preparation of sections for histopathological examination
Animals were sacriﬁced; liver, pancreas and kidney samples of
3–4 rats of each group were isolated immediately. Kidneys
were opened along the convex side to insure good ﬁxation
and then all samples were ﬁxed in 10% formalin prepared in
saline for at least 3 days. Afterward, all the specimens were
washed in tap water for half an hour and then dehydrated
using ascending grades of alcohol (70%, 80%, 90% and ﬁnally
absolute alcohol). Specimens were then cleared in xylene and
impregnated in soft parafﬁn wax at 55 C and embedded in
hard parafﬁn. Sections of 6 lm thickness were cut using a slide
microtome then, stained with hematoxylin and eosin12 for his-
topathological examination. Images were captured and pro-
cessed using Adobe Photoshop version 8.
2.7. Statistical analysis
Data were expressed as mean values ± SEM. Comparison be-
tween the mean values of different groups was carried out by
using one way analysis of variance (ANOVA) followed by
Tukey–Kramer post hoc test for multiple comparisons. In all
data analysis, p 6 0.05 was considered signiﬁcant.
3. Results
3.1. Effect of CoQ and/or Rosi on weight gain
During the experimental period, FED resulted in a gradual in-
crease in body weight starting from the third week after initia-
tion of the diet and continued thereafter. An average weight
gain of 56%was reached by the end of the experiment compared
to 34% for the normal-control group. Treatment of insulin-
resistant rats with Rosi was not associated with any signiﬁcant
change in body weight gain of FED-fed rats; however adminis-Figure 1 Effect of 6 weeks of oral treatment with rosiglitazone (Rosi;
body weight gain of insulin resistant rats fed for 16 weeks with fruct
(n= 8–10). *Signiﬁcantly different from normal-control group at p 6tration of CoQ and its combination with Rosi reduced the in-
creased bodyweight gain by 57%and 62%, respectively (Fig. 1).3.2. Effect of CoQ and/or Rosi on glucose homeostasis, lipid
proﬁle, cytokines, kidney function and antioxidant enzymes
The level of FBG was nearly doubled in the serum of FED-
control rats. Treatment with CoQ, Rosi and their combination
signiﬁcantly decreased FBG by 39%, 20% and 44%, respec-
tively. At the same time, insulin level was increased in the ser-
um of FED-control rats by nearly 2 folds. Treatment with Rosi
alone or combined with CoQ did not affect this increased level,
but it was almost normalized by the treatment with CoQ. The
increased levels of FBG and insulin of FED-fed rats resulted in
nearly a 4-fold rise in the HOMA-IR score. Treatment with
CoQ, Rosi or their combination lowered the raised score by
approximately 70%, 34% and 43%, respectively (Table 1).
Metabolic syndrome was also associated with a 2-fold in-
crease in serum leptin level. Treatment with the selected agents
was accompanied by normalization of this increased level. In
addition, the sera of FED-fed rats showed a marked elevation
in the level of the pro-inﬂammatory cytokine, TNF-a, by
125%. Treatment with CoQ, Rosi or their combination signif-
icantly decreased the raised level by 73%, 77%, and 78%,
respectively (Fig. 2).
Moreover, insulin resistance syndrome was accompanied
by marked dyslipidemia as evidenced by the observed increase
in the levels of total cholesterol, LDL-C and TGs paralleled to
reduction of HDL-C level, which was found to be nearly
halved following the FED. Treatment with CoQ resulted in a
40% reduction in TGs level and a 24% elevation in the
HDL-C level; however it was not associated with any signiﬁ-
cant change in the total cholesterol and LDL-C levels. Simi-
larly, treatment of FED-fed rats with Rosi did not result in
any marked alteration in FED-induced dyslipidemia. On the
other hand, a combined treatment with CoQ and Rosi reduced
the elevated total-cholesterol, LDL-C and TGs levels by 34%,
31% and 36%, respectively, paralleled to 123% elevation in
the HDL-C level (Fig. 3).
Compromised kidney function was another important as-
pect of the disease, results of the current study showed that
insulin-resistance syndrome was associated with 69% elevation
in uric acid level and with 3- and 2-fold increases in serum urea
and creatinine levels, respectively. Treatment with CoQ, Rosi
and their combination lowered the raised uric acid level by4 mg/kg), co-enzyme Q10 (CoQ; 10 mg/kg) or their combination on
ose-enriched diet (FED). Results are expressed as means ± SEM
0.05. #Signiﬁcantly different from FED-control group at p 6 0.05.
Figure 2 Effect of 6 weeks of oral treatment with rosiglitazone (Rosi; 4 mg/kg), co-enzyme Q10 (CoQ; 10 mg/kg) or their combination on
serum leptin and tumor necrosis factor-alpha (TNF-a) levels of insulin resistant rats fed for 16 weeks with fructose-enriched diet (FED).
Results are expressed as means ± SEM (n= 8–10). *Signiﬁcantly different from normal-control group at p 6 0.05. #Signiﬁcantly different
from FED-control group at p 6 0.05.
Table 1 Effect of 6 weeks of daily treatment with rosiglitazone (Rosi), co-enzyme Q10 (CoQ) or their combination on fasting blood
glucose (FBG) and insulin levels, as well as, HOMA-IR score of insulin resistant rats.
Normal-control Fructose-fed
Control Rosi (4 mg/kg) CoQ (10 mg/kg) Rosi + CoQ
FBG (mg/dl) 67.13 ± 4.07 130.70 ± 2.78* 104.12 ± 4.18*# 79.73 ± 4.50# 73.84 ± 5.54*#$
Insulin (lIU/ml) 12.95 ± 0.42 24.10 ± 2.97* 21.71 ± 2.49* 12.52 ± 0.46#$ 26.88 ± 2.87*
HOMA-IR score 4.52 ± 0.52# 7.96 ± 1.14* 5.28 ± 0.29*# 2.39 ± 0.14#$ 4.52 ± 0.52*
HOMA-IR: homeostasis model assessment of insulin resistance. Insulin resistance was induced by feeding rats with fructose enriched diet for
16 weeks.
Results are expressed as means ± SEM (n= 8–10).
* Signiﬁcantly different from normal-control group at p 6 0.05.
# Signiﬁcantly different from fructose-fed group at p 6 0.05.
$ Signiﬁcantly different from Rosi-treated group at p 6 0.05.
Figure 3 Effect of 6 weeks of oral treatment with rosiglitazone (Rosi; 4 mg/kg), co-enzyme Q10 (CoQ; 10 mg/kg) or their combination on
serum lipid proﬁle of insulin resistant rats fed for 16 weeks with fructose-enriched diet (FED). Results are expressed as means ± SEM
(n= 8–10). *Signiﬁcantly different from normal-control group at p 6 0.05. #Signiﬁcantly different from FED-control group at p 6 0.05.
$Signiﬁcantly different from Rosi-treated group at p 6 0.05.
16 S.M. Mansour et al.54%, 41% and 23%, respectively. Similarly, the administra-
tion of CoQ to FED-fed reduced the elevated urea level by
51%, however the administration of either Rosi alone or in
combination with CoQ did not show any signiﬁcant change
in the raised urea level. In the same way, treatment with
CoQ and/or Rosi had no effect on the elevated creatinine level
(Table 2).
Furthermore, fructose-induced MS was accompanied by a
marked oxidative insult as evidenced by the observed 3-
and 9-fold reductions in the plasma activities of catalase and
GSH-Px. Treatment with CoQ alone resulted in a markedincrease in the catalase activity by 108%. On the other hand,
CoQ in combination with Rosi almost normalized the reduced
GSH-Px activity (Fig. 4).3.3. Effect of Rosi or CoQ and their combination on histological
changes
3.3.1. Liver samples
FED-control rats showed marked dilatation and congestion in
the central and portal veins with severe ﬁbrosis extending from
Table 2 Effect of 6 weeks of daily treatment with rosiglitazone (Rosi), co-enzyme Q10 (CoQ) or their combination on serum uric acid,
urea and creatinine, levels of insulin resistant rats.
Normal-control Fructose-fed
Control Rosi (4 mg/kg) CoQ (10 mg/kg) Rosi + CoQ
Uric acid (mg/dl) 2.22 ± 0.13 7.05 ± 0.31* 4.16 ± 0.52*# 3.23 ± 0.30# 5.42 ± 0.43*#
Urea (mg/dl) 6.94 ± 1.04 17.73 ± 1.17* 16.43 ± 1.06* 8.74 ± 0.59#$ 15.64 ± 1.33*
Creatinine (mg/dl) 0.31 ± 0.042 0.71 ± 0.044* 0.73 ± 0.073* 0.63 ± 0.08* 0.57 ± 0.06*
Insulin resistance was induced by feeding rats with fructose enriched diet for 16 weeks.
Results are expressed as means ± SEM (n= 8–10).
* Signiﬁcantly different from normal-control group at p 6 0.05.
# Signiﬁcantly different from fructose-fed group at p 6 0.05.
$ Signiﬁcantly different from Rosi-treated group at p 6 0.05.
Figure 4 Effect of 6 weeks of oral treatment with rosiglitazone (Rosi; 4 mg/kg), co-enzyme Q10 (CoQ; 10 mg/kg) or their combination on
plasma catalase and glutathione peroxidase (GSH-Px) activities of insulin resistant rats fed for 16 weeks with fructose-enriched diet
(FED). Results are expressed as means ± SEM (n= 8–10). *Signiﬁcantly different from normal-control group at p 6 0.05. #Signiﬁcantly
different from FED-control group at p 6 0.05. $Signiﬁcantly different from Rosi-treated group at p 6 0.05. @Signiﬁcantly different form
CoQ-treated group at p 6 0.05.
Beneﬁcial effects of co-enzyme Q10 and rosiglitazone in fructose-induced metabolic syndrome in rats 17the portal area in between hepatocytes distorting the normal
architecture of liver tissue. The hepatocytes showed marked
fatty changes and hydropic degeneration in a diffuse manner,
an effect that was reversed by the treatment with Rosi. Treat-
ment of insulin resistant rats with CoQ showed marked
improvement in the hepatic structure however, hydropic
degeneration in the hepatocytes especially in the zone sur-
rounding the portal area was still present. The combination
of both agents showed an almost normal hepatic structure.
However, few individual hepatocytes still showed some fatty
changes (Fig. 5).
3.3.2. Kidney samples
Histopathological examination of renal sections of FED-
control rats showed focal hemorrhage with congestion in the
cortical blood vessels and degeneration in the lining endothe-
lium of the tubules. Proliferation in the lining endothelium
of the glomerular tuft and focal inﬂammatory cell inﬁltration
in between the tubules was also noticed. Treatment with Rosi
alone or in combination with CoQ markedly reduced focal
hemorrhage and inﬂammatory cell inﬁltration however,
congestion in the glomerular tuft was still observed. However,
single treatment with CoQ showed vacuolization in the lining
endothelium of the congested glomerular tuft associated with
focal inﬂammatory cells’ inﬁltration. Focal hemorrhage in
between the tubules was also noticed (Fig. 5).3.3.3. Pancreas samples
Pancreatic sections of insulin resistant rats showed marked
hypertrophy in the islets of Langerhan’s in a diffuse manner.
Fibrosis within the lobules of the pancreas with thickening
of the blood vessel walls was observed. Islets of Langerhan’s
showed a slight increase in the amount of the connective tissue
in between the cells. Treatment with Rosi restored the normal
structure of the pancreas however, CoQ alone or in combina-
tion with Rosi showed diffuse manner hypertrophy all over the
islets of Langerhan’s and the congestion in the lobular blood
vessels accompanied by very ﬁne ﬁbrosis among these blood
vessels. Cystic dilatation in the ducts of exocrine acini was also
observed (Fig. 5).
4. Discussion
MS has become a worldwide health problem. Since, it is difﬁ-
cult for patients to follow a diet and/or exercise regimens that
would improve their symptoms, therefore the investigation of
agents that may deal with the serious aspects of the disease
is an important ﬁeld of research. Micronutrients such as natu-
ral antioxidants have received recently a great deal of attention
with respect to their efﬁcacy in treating the insulin-resistance
syndrome complications. CoQ is a naturally occurring potent
antioxidant with proven efﬁcacy in a wide range of diseases.
It has also been shown to lower glycated hemoglobin levels
Figure 5 Effect of 6 weeks of oral treatment with rosiglitazone (Rosi; 4 mg/kg), co-enzyme Q10 (CoQ; 10 mg/kg) or their combination on
structure of different organs isolated from insulin resistant rats. Tissues were stained with hematoxylin and eosin (magniﬁcation · 200). (a)
Normal hepatic tissue showing polyhedral hepatocytes with eosinophilic cytoplasm and large rounded vesicular nuclei. (b) FED hepatic
tissue with marked dilatation and congestion in central and portal veins with ﬁbrosis, fatty changes and hydropic degeneration. (c) Rosi-
treated FED-rats with normal hepatic structure. (d) CoQ-treated FED rats showing general hepatic tissue improvement, hydropic
degeneration in the hepatocytes especially those surrounding the portal area was still observed (e) (Rosi + CoQ)-treated FED rats
showing normal hepatocyte appearance but with few individual hepatocytes showing fatty changes (f) Normal renal tissue showing
glomerulus that is located between many tubules. (g) FED renal tissue with focal hemorrhage, congestion in cortical blood vessels and
proliferation in lining epithelium. (h) Rosi-treated FED rats with marked improvement in renal tissue, congestion in glomerular tuft still
observed. (i) CoQ-treated FED rats showing vacuolization of lining endothelium of the congested glomeruli tuft and focal inﬂammatory
cells inﬁltration in between the tubules. (j) (Rosi + CoQ)-treated FED rats showing swelling and vacuolization of the endothelial cells
lining the glomerular tuft. (k) Normal pancreatic structure showing serous acini located in lobules, which contains islets of Langerhan’s. (l)
FED pancreatic tissue with diffuse manner hypertrophy in islets of Langerhan’s with ﬁbrosis in the lobules and thickening in blood vessel
walls. (m) Rosi-treated FED rats with normal pancreatic structure. (n) CoQ-treated rats showing diffuse manner hypertrophy all over the
islets of Langerhans. (o) (Rosi + CoQ)-treated rats showing congestion in the lobular blood vessels accompanied with very ﬁne ﬁbrosis
among these blood vessels and cystic dilatation in the ducts of the exocrine acini.
18 S.M. Mansour et al.and lipid peroxidation products while raising the level of some
antioxidant enzymes in the pancreas of diabetic rats,4 suggest-
ing that CoQ may possess protective effects against fructose-
induced changes in rats.
In the present study, maintaining rats on FED for 16 weeks
was associated with multiple disorders including increased
weight gain, hyperglycemia, dyslipidemia, hyperinsulinemia,
hyperleptinemia, abdominal obesity, hyperuricemia, oxidative
stress and insulin resistance.
Treatment of FED-fed rats with Rosi reduced insulin resis-
tance and hyperglycemia. Moreover, it normalized the elevated
leptin level as well as normalized fructose-induced pancreatic
histopathological changes. These changes are in accordance
with those of To¨ru¨ner et al.13 who reported that Rosi was able
to reduce plasma leptin concentration. Lustig et al.14 also re-
ported that reduction of insulinemia improves insulin resis-
tance and leptin sensitivity.
Despite the fact that treatment with Rosi (4 mg/kg/day) re-
duced the elevated serum leptin level, it maintained the in-
creased body weight gain of FED-fed rats. This ﬁnding is
quite consistent with that of Iozzo et al.15 who found that
monotherapy with Rosi (8 mg/day) in obese-diabetic patients
was associated with insigniﬁcant changes in body weight. In
addition, To¨ru¨ner et al.13 reported that rats treated with Rosi
(30 mg/kg/day) gained more weight as compared to their
respective controls.Treatment of insulin-resistant rats with CoQ reduced insu-
linemia, hyperglycemia, insulin resistance and leptin level. In
addition, it signiﬁcantly decreased body weight gain. In har-
mony with the present results, Rauscher et al.5 showed that
CoQ supplementation in STZ-diabetic rats attenuated most
of diabetic-induced changes. The combination of Rosi and
CoQ behaved in the same manner and resulted in a further
reduction of insulinemia, hyperglycemia, insulin resistance
and leptin level. Furthermore, it markedly reduced body
weight gain in FED-fed rats.
Co-enzyme Q10 is an essential part of the cellular machinery
used to produce ATP, which provides the energy for muscle
contraction and other vital cellular functions.16 Increased en-
ergy production may speed up metabolism and accelerate
weight loss as that observed in the current study. Hill et al.17
reported that blood leptin levels decrease considerably during
weight loss with subsequent reduction in the number and size
of fat cells, a fact that may explain the observed decline in the
elevated serum leptin levels of FED-fed rats treated with CoQ.
On the contrary, results of the current study revealed that the
treatment of FED-fed rats with CoQ did not show any
improvement of FED-induced histopathological changes, a
ﬁnding that may necessitate further investigation.
Disturbed lipid metabolism is considered as another charac-
teristic feature of MS. The current study shows that supplying
rats with FED elevated the levels of TGs, LDL-C and total
Beneﬁcial effects of co-enzyme Q10 and rosiglitazone in fructose-induced metabolic syndrome in rats 19cholesterol in serum. These results are in harmony with those of
other investigators.18,19 On the other hand, HDL-C level was
markedly reduced in the serum of FED-fed rats. This ﬁnding
was in accordance with that of Ohmori et al. who reported a de-
crease in serum HDL-C after 4-weeks of fructose feeding.20
The results of the present study revealed that the treatment
of FED-fed rats with Rosi did not show any signiﬁcant
improvement in FED-induced dyslipidemia. This ﬁnding is
consistent with that of Goldberg et al.21 who reported that
the treatment of patients with type-2 diabetes and dyslipidemia
with Rosi was associated with a signiﬁcant increase in serum
levels of TGs, total cholesterol, LDL-C and HDL-C. Similarly,
Ko et al.22 reported that Rosi treatment in type-2 diabetes was
associated with a signiﬁcant increase in serum total cholesterol,
HDL-C and LDL-C in comparison to the control group. Re-
cently, it was shown that the addition of Rosi to an existing
anti-diabetic medication regimen improves glycemic control
to a lesser extent when compared to metformin or sulfonylu-
reas, and may be accompanied by deterioration of patients’
lipid proﬁles.23 Similarly, the administration of CoQ to insu-
lin-resistant rats did not show any signiﬁcant change in the
deteriorated lipid proﬁle. In a similar fashion, Kunitomo
et al.24 revealed that CoQ supplementation to genetically in-
duced insulin resistant rats prevented the elevated insulin levels
without affecting dyslipidemia.
In contrast to the individual effect of either Rosi or CoQ,
the combined treatment of both agents markedly reduced the
elevated total cholesterol, LDL-C and TG levels parallel to
an elevation in HDL-C level. Several studies documented the
potential role of Rosi and CoQ on hypertriglyceridemia in
insulin-resistant states. Rosi treatment was shown to improve
hypertriglyceridemia by increasing fat oxidation in the muscles
and in the liver as well as the redistribution of circulating TGs
in the tissue.25,26 Regarding the effect of CoQ, Modi et al.27 re-
ported that the administration of CoQ to STZ-diabetic rats for
4 weeks resulted in a signiﬁcant decrease in serum TGs level, a
ﬁnding that is consistent with the present results.
The results of the current study also showed that, the treat-
ment of FED-fed rats with Rosi resulted in normalization of
fructose-induced histopathological changes of the liver tissue
which included severe congestion together with hydropic
degeneration and notable fatty changes in the hepatocytes.
Quite consistent with the aforementioned ﬁndings, Tahan
et al.28 reported that Rosi attenuated liver inﬂammation in a
rat model of non-alcoholic steatohepatitis. Beneﬁcial effects
of Rosi could be explained by its anti-inﬂammatory effect
mediated by the activation of PPARc on macrophages29
resulting in a decreased production of the pro-inﬂammatory
cytokines known to be implicated in the pathogenesis of
non-alcoholic fatty liver disease, such as interleukin-1b (IL-
1b), interleukin-6 (IL-6) and TNF-a.
On the other hand, the administration of CoQ alone or in
combination with Rosi showed a mild improvement in FED-
induced histopathological changes in the liver. The current
ﬁnding is in contrast to those of other investigators who
reported the favorable effects of such micronutrients in hepa-
tocellular injury.30 This contradiction may require further
investigation in order to determine the exact responsible
mechanism.
The results of the present study also revealed that supplying
rats with a FED elevated serum uric acid level. In FED-fed
rats, increased plasma uric acid levels have been reported bymany authors.31,32 Unlike other simple sugars, fructose has
the unique ability to increase uric acid production. The ﬁrst
step in the metabolism of fructose is the phosphorylation to
fructose-1-P via fructokinase, an enzyme which utilizes adeno-
sine monophosphate (ATP) as a phosphate donor. The accu-
mulation of fructose-1-P depletes hepatic ATP and generates
adenosine diphosphate (ADP). Metabolism of ADP stimulates
adenosine monophosphate (AMP) deaminase and increases
the degradation of nucleotides to form uric acid.33
Treatment of insulin-resistant rats with Rosi or CoQ signif-
icantly lowered serum uric acid level. Amelioration of insulin
resistance by insulin sensitizers was shown to decrease serum
uric acid level.34 The favorable effects of CoQ could be due
to its antioxidant properties thus, inhibiting lipid peroxidation
by preventing the production of lipid peroxyl radicals.24 In
addition, CoQ administration resulted in the reduction of
hyperinsulinemia and insulin resistance consequently, uric acid
excretion is increased and lower levels are observed in the ser-
um.35 A typical consequence for the complementary effect of
both Rosi and CoQ was also observed in the current study
as the combined agents succeeded in normalizing the elevated
serum uric acid level.
Furthermore, the ﬁndings of the present study demon-
strated that MS in rats was associated with an elevation in ser-
um urea and creatinine levels which reﬂects impairment in
glomerular ﬁltration rate. This was further supported by histo-
logical examination of kidney tissues which revealed hemor-
rhage, congestion and inﬂammatory cell inﬁltration of the
glomerular tuft. Treatment of insulin-resistant rats with Rosi
or its combination with CoQ failed to provoke any signiﬁcant
change in the elevated levels of serum urea and creatinine;
however they partly improved hemorrhage and inﬂammatory
cell inﬁltration of the glomerular tuft although congestion in
the tuft was still observed, a fact that may explain the observed
ineffectiveness of Rosi or its combination with CoQ on the ser-
um levels of urea and creatinine.
Low-grade inﬂammation is now recognized as a common
feature of the metabolic abnormalities observed in obesity.36
TNF-a is increased in obesity and has been extensively charac-
terized for its role in insulin resistance.37 Fructose feeding in
rats has been shown to increase hydrogen peroxide generation
and inﬂammatory markers.38 Increased plasma concentrations
of TNF-a have been observed following fructose feeding in
mice.39 Furthermore, TNF-a mRNA increased in hepatic tis-
sues of fructose-fed mice.40 These ﬁndings are in harmony with
the results of the present study which showed that maintaining
rats on an FED for 16 weeks deﬁnitely increased serum TNF-a
level.
The results of the present study demonstrated that treating
MS rats with Rosi, CoQ or their combination markedly de-
creased serum TNF-a level. These ﬁndings are quite consistent
with those of Lee et al.41 who showed that treating Otsuka
Long-Evans Tokushima fatty rats with Rosi reduced serum
inﬂammatory cytokines including TNF-a. Regarding the effect
of CoQ, limited data are available in the literature. However,
Bessler et al.42 found that incubation of human peripheral
blood mononuclear cells with CoQ markedly reduced TNF-a
secretion.
Furthermore, the results of the present study revealed that
maintaining rats on an FED for 16 weeks reduced the activities
of the antioxidant enzymes; catalase and GSH-Px. Delbosc
et al. found that fructose feeding increases oxidative stress
20 S.M. Mansour et al.and is associated with MS in rodents.43 Enhanced lipid perox-
idation in fructose-fed rats could be associated with high circu-
lating glucose levels, which enhance free radical production
from glucose autoxidation and protein glycation. Prolonged
exposure of rats to hyperglycemic conditions reduces the activ-
ities of superoxide dismutase and other antioxidant enzymes.44
Treating insulin resistant rats with Rosi slightly raised the
reduced plasma catalase and GSH-Px activities. Yilmaz et al.
reported the antioxidant properties of the drug and found that
Rosi treatment reduced malondialdehyde (MDA) level, a valu-
able indicator of lipid peroxidation in subjects with MS.45 The
antioxidant effect of Rosi is not mediated by PPAR-c but
strictly depends on its ability to activate AMP-activated pro-
tein kinase which in turn, prevents the activity of NADPH-
oxidase,46 a major source for the production of ROS after
exposure to hyperglycemia.47 In addition, Sener et al. reported
that treatment with Rosi decreased MDA contents of the liver
in rats by inhibiting neutrophil inﬁltration and the subsequent
activation of inﬂammatory mediators that induce lipid perox-
idation.48 This ﬁnding was supported in the present study by
the fact that Rosi treatment reversed FED-induced histopa-
thological changes in the livers of insulin resistant rats.
Likewise, CoQ treatment was associated with a mild eleva-
tion in the activities of catalase and GSH-Px enzymes. Antiox-
idant potential of CoQ is related to its capacity to exist in a
completely oxidized form and a completely reduced form thus,
enabling it to perform its functions in the electron transport
chain.24 CoQ inhibits lipid peroxidation by preventing the pro-
duction of lipid peroxyl radicals. In contrast to other antioxi-
dants, this compound inhibits both the initiation and the
propagation of lipid and protein oxidation. It also regenerates
other antioxidants such as vitamin E.24 These data could ex-
plain the favorable effects of Rosi and CoQ in this perspective.
5. Conclusions
In conclusion, the ﬁndings of the current study prove the ben-
eﬁts of the co-administration of Rosi and CoQ in a fructose-
induced model of insulin resistance. Rosi and CoQ, in
combination, offer further improvements to markers of disease
risk, including lipid proﬁle, hyperglycemia hyperinsulinemia,
hyperleptinemia, increased oxidative stress and the level of
circulating cytokines.
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